NASDAQ:CLLS Cellectis (CLLS) Stock Price, News & Analysis $2.63 0.00 (0.00%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$2.62 -0.01 (-0.38%) As of 07/17/2026 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cellectis Stock (NASDAQ:CLLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cellectis alerts:Sign Up Key Stats Today's Range$2.62▼$2.7050-Day Range$2.63▼$4.0752-Week Range$1.77▼$5.48Volume8,005 shsAverage Volume20,953 shsMarket Capitalization$263.89 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company Overview Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors. The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies. Its pipeline includes multiple CAR‐T candidates, such as those targeting CD19 and CD22 antigens for B‐cell malignancies and other programs addressing acute myeloid leukemia. Cellectis advances these investigational therapies through preclinical research and early‐ to mid‐stage clinical trials, often in partnership with leading pharmaceutical firms to enhance development and commercialization capabilities. Cellectis operates research and process development laboratories as well as GMP manufacturing facilities across Europe and North America. Clinical trials are conducted in premier cancer centers in the United States and Europe, reflecting the company’s global reach. Strategic collaborations and licensing agreements support the expansion of its gene‐edited therapies into new indications and geographic markets, with an emphasis on scalable production and regulatory readiness. Under the leadership of founder and Chief Executive Officer Dr. André Choulika, Cellectis has established itself as a pioneer in TALEN‐based genome editing. The management team combines scientific and commercial expertise to drive innovation, with a focus on delivering next‐generation allogeneic CAR‐T therapies to patients worldwide.AI Generated. May Contain Errors. Read More Cellectis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreCLLS MarketRank™: Cellectis scored higher than 51% of companies evaluated by MarketBeat, and ranked 407th out of 842 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingCellectis has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCellectis has a consensus price target of $7.00, representing about 166.2% upside from its current price of $2.63.Amount of Analyst CoverageCellectis has only been the subject of 1 research reports in the past 90 days.Read more about Cellectis' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectis is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectis is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectis has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cellectis' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.38% of the float of Cellectis has been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 8.86.Change versus previous monthShort interest in Cellectis has recently decreased by 13.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCellectis does not currently pay a dividend.Dividend GrowthCellectis does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment0.67 News SentimentCellectis has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cellectis this week, compared to 2 articles on an average week. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cellectis insiders have not sold or bought any company stock.Percentage Held by Insiders16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cellectis' insider trading history. Receive CLLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLLS Stock News HeadlinesProlynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease PortfolioJuly 15, 2026 | globenewswire.comCellectis Sets 2026 Clinical Milestones and Extends Cash Runway Into H2 2027July 2, 2026 | theglobeandmail.comNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried to acquire it outright for $40 billion - the White House blocked the deal on national security grounds. So NVIDIA settled for a 20-year supply deal instead. Its architecture delivers '2-3x performance per watt' by NVIDIA's own admission, and its data-center royalties more than doubled last quarter. Analyst Dylan Jovine - who called Palantir at $7.38 and Rocket Lab at $3.80 - has named it his number-one pick ahead of its July 29th earnings report. | Behind the Markets (Ad)Cellectis Shareholders Approve Board-Backed Resolutions at June 25, 2026 MeetingJune 25, 2026 | tipranks.comCellectis Shareholders Approve 2025 Accounts and Expand Capital-Raising Powers at June 25 MeetingJune 25, 2026 | tipranks.comCellectis Reports Results from Shareholders Meeting Held on June 25, 2026June 25, 2026 | globenewswire.comCellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 CongressJune 11, 2026 | globenewswire.comCLLS stock rallies over 24% after hours — here's whyJune 9, 2026 | msn.comSee More Headlines CLLS Stock Analysis - Frequently Asked Questions How have CLLS shares performed this year? Cellectis' stock was trading at $4.84 at the beginning of the year. Since then, CLLS shares have decreased by 45.7% and is now trading at $2.63. How were Cellectis' earnings last quarter? Cellectis S.A. (NASDAQ:CLLS) announced its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.08. The biotechnology company had revenue of $7.55 million for the quarter, compared to analysts' expectations of $11.04 million. Cellectis had a negative trailing twelve-month return on equity of 80.66% and a negative net margin of 89.51%. When did Cellectis IPO? Cellectis (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager. How do I buy shares of Cellectis? Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cellectis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Alibaba Group (BABA). Company Calendar Last Earnings5/11/2026Today7/20/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CLLS's financial health is in the Yellow zone, according to TradeSmith. CLLS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLLS CIK1627281 Webwww.cellectis.com Phone(318) 169-1600Fax33-1-81-69-16-06Employees290Year Founded1999Price Target and Rating Average Price Target for Cellectis$7.00 High Price Target$9.00 Low Price Target$4.00 Potential Upside/Downside+166.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.59 million Net Margins-89.51% Pretax Margin-90.01% Return on Equity-80.66% Return on Assets-20.51% Debt Debt-to-Equity Ratio1.13 Current Ratio1.52 Quick Ratio1.52 Sales & Book Value Annual Sales$79.59 million Price / Sales3.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book3.46Miscellaneous Outstanding Shares100,340,000Free Float83,873,000Market Cap$263.89 million OptionableOptionable Beta2.88 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CLLS) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredPrint this and keep it by your screenEver been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...Profits Run | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
